The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Protein Vaccine Market Research Report 2025
Synopsis
Recombinant Protein Vaccine refers to the vaccines manufactured using recombinant DNA technology
The global Recombinant Protein Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion US$ in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion US$ in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Recombinant Protein Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Protein Vaccine.
Report Scope
The Recombinant Protein Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Protein Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Protein Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
GSK
Sanofi
Zoties
Elanco
Boehringer-Ingelheim
Indian Immunologicals
Plumbline Life Sciences
Novavax
Medicago
Pukang Biologic Technology
Johnson & Johnson
Clover Biopharmaceuticals
Suzhou Yuzhibo Biotechnology
Segment by Type
Bacterial Cells Culture
Mammalian Cells Culture
Segment by Application
Human
Animal
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Protein Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Protein Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Recombinant Protein Vaccine refers to the vaccines manufactured using recombinant DNA technology
The global Recombinant Protein Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion US$ in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion US$ in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Recombinant Protein Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Protein Vaccine.
Report Scope
The Recombinant Protein Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Protein Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Protein Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
GSK
Sanofi
Zoties
Elanco
Boehringer-Ingelheim
Indian Immunologicals
Plumbline Life Sciences
Novavax
Medicago
Pukang Biologic Technology
Johnson & Johnson
Clover Biopharmaceuticals
Suzhou Yuzhibo Biotechnology
Segment by Type
Bacterial Cells Culture
Mammalian Cells Culture
Segment by Application
Human
Animal
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Protein Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Protein Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Recombinant Protein Vaccine Market Overview
1.1 Product Overview and Scope of Recombinant Protein Vaccine
1.2 Recombinant Protein Vaccine Segment by Type
1.2.1 Global Recombinant Protein Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Bacterial Cells Culture
1.2.3 Mammalian Cells Culture
1.3 Recombinant Protein Vaccine Segment by Application
1.3.1 Global Recombinant Protein Vaccine Market Value by Application: (2024-2030)
1.3.2 Human
1.3.3 Animal
1.4 Global Recombinant Protein Vaccine Market Size Estimates and Forecasts
1.4.1 Global Recombinant Protein Vaccine Revenue 2019-2030
1.4.2 Global Recombinant Protein Vaccine Sales 2019-2030
1.4.3 Global Recombinant Protein Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Protein Vaccine Market Competition by Manufacturers
2.1 Global Recombinant Protein Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Protein Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Protein Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Protein Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Protein Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Protein Vaccine, Product Type & Application
2.7 Recombinant Protein Vaccine Market Competitive Situation and Trends
2.7.1 Recombinant Protein Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Protein Vaccine Players Market Share by Revenue
2.7.3 Global Recombinant Protein Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Protein Vaccine Retrospective Market Scenario by Region
3.1 Global Recombinant Protein Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Protein Vaccine Global Recombinant Protein Vaccine Sales by Region: 2019-2030
3.2.1 Global Recombinant Protein Vaccine Sales by Region: 2019-2024
3.2.2 Global Recombinant Protein Vaccine Sales by Region: 2025-2030
3.3 Global Recombinant Protein Vaccine Global Recombinant Protein Vaccine Revenue by Region: 2019-2030
3.3.1 Global Recombinant Protein Vaccine Revenue by Region: 2019-2024
3.3.2 Global Recombinant Protein Vaccine Revenue by Region: 2025-2030
3.4 North America Recombinant Protein Vaccine Market Facts & Figures by Country
3.4.1 North America Recombinant Protein Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Protein Vaccine Sales by Country (2019-2030)
3.4.3 North America Recombinant Protein Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Protein Vaccine Market Facts & Figures by Country
3.5.1 Europe Recombinant Protein Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Protein Vaccine Sales by Country (2019-2030)
3.5.3 Europe Recombinant Protein Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Protein Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Protein Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Protein Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Protein Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Protein Vaccine Market Facts & Figures by Country
3.7.1 Latin America Recombinant Protein Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Protein Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Protein Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Protein Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Protein Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Protein Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Protein Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Protein Vaccine Sales by Type (2019-2030)
4.1.1 Global Recombinant Protein Vaccine Sales by Type (2019-2024)
4.1.2 Global Recombinant Protein Vaccine Sales by Type (2025-2030)
4.1.3 Global Recombinant Protein Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Protein Vaccine Revenue by Type (2019-2030)
4.2.1 Global Recombinant Protein Vaccine Revenue by Type (2019-2024)
4.2.2 Global Recombinant Protein Vaccine Revenue by Type (2025-2030)
4.2.3 Global Recombinant Protein Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Protein Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Protein Vaccine Sales by Application (2019-2030)
5.1.1 Global Recombinant Protein Vaccine Sales by Application (2019-2024)
5.1.2 Global Recombinant Protein Vaccine Sales by Application (2025-2030)
5.1.3 Global Recombinant Protein Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Protein Vaccine Revenue by Application (2019-2030)
5.2.1 Global Recombinant Protein Vaccine Revenue by Application (2019-2024)
5.2.2 Global Recombinant Protein Vaccine Revenue by Application (2025-2030)
5.2.3 Global Recombinant Protein Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Protein Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Recombinant Protein Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Recombinant Protein Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Recombinant Protein Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Zoties
6.4.1 Zoties Corporation Information
6.4.2 Zoties Description and Business Overview
6.4.3 Zoties Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Zoties Recombinant Protein Vaccine Product Portfolio
6.4.5 Zoties Recent Developments/Updates
6.5 Elanco
6.5.1 Elanco Corporation Information
6.5.2 Elanco Description and Business Overview
6.5.3 Elanco Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Elanco Recombinant Protein Vaccine Product Portfolio
6.5.5 Elanco Recent Developments/Updates
6.6 Boehringer-Ingelheim
6.6.1 Boehringer-Ingelheim Corporation Information
6.6.2 Boehringer-Ingelheim Description and Business Overview
6.6.3 Boehringer-Ingelheim Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Boehringer-Ingelheim Recombinant Protein Vaccine Product Portfolio
6.6.5 Boehringer-Ingelheim Recent Developments/Updates
6.7 Indian Immunologicals
6.6.1 Indian Immunologicals Corporation Information
6.6.2 Indian Immunologicals Description and Business Overview
6.6.3 Indian Immunologicals Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Indian Immunologicals Recombinant Protein Vaccine Product Portfolio
6.7.5 Indian Immunologicals Recent Developments/Updates
6.8 Plumbline Life Sciences
6.8.1 Plumbline Life Sciences Corporation Information
6.8.2 Plumbline Life Sciences Description and Business Overview
6.8.3 Plumbline Life Sciences Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Plumbline Life Sciences Recombinant Protein Vaccine Product Portfolio
6.8.5 Plumbline Life Sciences Recent Developments/Updates
6.9 Novavax
6.9.1 Novavax Corporation Information
6.9.2 Novavax Description and Business Overview
6.9.3 Novavax Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Novavax Recombinant Protein Vaccine Product Portfolio
6.9.5 Novavax Recent Developments/Updates
6.10 Medicago
6.10.1 Medicago Corporation Information
6.10.2 Medicago Description and Business Overview
6.10.3 Medicago Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Medicago Recombinant Protein Vaccine Product Portfolio
6.10.5 Medicago Recent Developments/Updates
6.11 Pukang Biologic Technology
6.11.1 Pukang Biologic Technology Corporation Information
6.11.2 Pukang Biologic Technology Recombinant Protein Vaccine Description and Business Overview
6.11.3 Pukang Biologic Technology Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Pukang Biologic Technology Recombinant Protein Vaccine Product Portfolio
6.11.5 Pukang Biologic Technology Recent Developments/Updates
6.12 Johnson & Johnson
6.12.1 Johnson & Johnson Corporation Information
6.12.2 Johnson & Johnson Recombinant Protein Vaccine Description and Business Overview
6.12.3 Johnson & Johnson Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Johnson & Johnson Recombinant Protein Vaccine Product Portfolio
6.12.5 Johnson & Johnson Recent Developments/Updates
6.13 Clover Biopharmaceuticals
6.13.1 Clover Biopharmaceuticals Corporation Information
6.13.2 Clover Biopharmaceuticals Recombinant Protein Vaccine Description and Business Overview
6.13.3 Clover Biopharmaceuticals Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Clover Biopharmaceuticals Recombinant Protein Vaccine Product Portfolio
6.13.5 Clover Biopharmaceuticals Recent Developments/Updates
6.14 Suzhou Yuzhibo Biotechnology
6.14.1 Suzhou Yuzhibo Biotechnology Corporation Information
6.14.2 Suzhou Yuzhibo Biotechnology Recombinant Protein Vaccine Description and Business Overview
6.14.3 Suzhou Yuzhibo Biotechnology Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Suzhou Yuzhibo Biotechnology Recombinant Protein Vaccine Product Portfolio
6.14.5 Suzhou Yuzhibo Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Protein Vaccine Industry Chain Analysis
7.2 Recombinant Protein Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Protein Vaccine Production Mode & Process
7.4 Recombinant Protein Vaccine Sales and Marketing
7.4.1 Recombinant Protein Vaccine Sales Channels
7.4.2 Recombinant Protein Vaccine Distributors
7.5 Recombinant Protein Vaccine Customers
8 Recombinant Protein Vaccine Market Dynamics
8.1 Recombinant Protein Vaccine Industry Trends
8.2 Recombinant Protein Vaccine Market Drivers
8.3 Recombinant Protein Vaccine Market Challenges
8.4 Recombinant Protein Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
